Literature DB >> 11432634

Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose.

M Sandherr1, C von Schilling, T Link, K Stock, N von Bubnoff, C Peschel, N Avril.   

Abstract

We report on a patient with Hodgkin's disease who presented with hypodense splenic lesions and corresponding increased glucose metabolism in FDG-PET imaging, four months after completion of initial treatment, suggestive of early relapse. Serological testing for toxoplasma gondii, however, showed evidence of a recently reactivated or newly acquired infection. Three weeks after immediate antibiotic treatment with Daraprime and Sulfadiazin, the splenic lesions had completely resolved. Additionally, serological titers for toxoplasma gondii were normalized and whole body FDG-PET imaging showed no metabolic activity. Although the positive predictive value of PET imaging to indicate lymphoma is reported to be higher than CT, hypermetabolic lesions are not specific for malignant tissue. Whereas benign tumors typically show low glucose metabolism, activated granulocytes and macrophages may display significantly increased glucose consumption. In conclusion, our case report shows that although therapeutic decisions are often based on the results of imaging modalities, the taking of a detailed history and the acquisition of histological confirmation of the suspected lymphoma relapse are also advisable where possible. Cellular immunodeficiency can result in severe infections even in patients with intermediate stage Hodgkin's lymphoma in remission after combined modality treatment. Therefore, despite the high sensitivity of FDG-PET imaging for the detection of recurrent lymphoma, the differential diagnosis of infectious lesions should be kept in mind, in particular in immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432634     DOI: 10.1023/a:1011136324038

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

1.  Toxoplasmic Lymphadenitis Mimicking a Metastatic Thyroid Carcinoma at (18)F-FDG-PET/CT.

Authors:  Giorgio Treglia; Massimo Bongiovanni; Luca Ceriani; Gaetano Paone; Luca Giovanella
Journal:  Nucl Med Mol Imaging       Date:  2013-09-13

2.  18F-FDG PET in malignant lymphoma: significance of positive findings.

Authors:  Paolo Castellucci; PierLuigi Zinzani; Michael Pourdehnad; Lapo Alinari; Cristina Nanni; Mohsen Farsad; Giuseppe Battista; Monica Tani; Vittorio Stefoni; Romeo Canini; Nino Monetti; Domenico Rubello; Abass Alavi; Roberto Franchi; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-23       Impact factor: 9.236

3.  Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment.

Authors:  Nicolas Graf; Ken Herrmann; Jürgen den Hollander; Falko Fend; Tibor Schuster; Hans-Jürgen Wester; Reingard Senekowitsch-Schmidtke; Christian Meyer zum Büschenfelde; Christian Peschel; Markus Schwaiger; Tobias Dechow; Andreas K Buck
Journal:  Mol Imaging Biol       Date:  2008-08-14       Impact factor: 3.488

Review 4.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

5.  Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.

Authors:  Andreas K Buck; Clemens Kratochwil; Gerhard Glatting; Malik Juweid; Martin Bommer; Djurdja Tepsic; Andreas T J Vogg; Torsten Mattfeldt; Bernd Neumaier; Peter Möller; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-31       Impact factor: 9.236

Review 6.  18F-FDG PET/CT imaging in oncology.

Authors:  Ahmad Almuhaideb; Nikolaos Papathanasiou; Jamshed Bomanji
Journal:  Ann Saudi Med       Date:  2011 Jan-Feb       Impact factor: 1.526

7.  Tuberculosis Coexistence in Pediatric Hodgkin's Lymphoma: A Tropical Country Experience.

Authors:  Maneya Padma; Nuthan Kumar; Jyothi Munireddy; Arun Kumar; Pooja Chebbi Gujjal; S Chennagiri Premalata
Journal:  South Asian J Cancer       Date:  2021-06-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.